Brincidofovir (CMX001) for the Treatment of Serious or Life-Threatening Double-Stranded DNA Virus Infections in Patients Receiving Liver Transplant as Part of Multiorgan Transplantation.
Diana F. Florescu(University of Nebraska Medical Center), Herve Momméja-Marin(Chimerix (United States)), Eneida R. Nemecek(Oregon Health & Science University), Gregory E. Chittick(Chimerix (United States)), Thomas M. Brundage(Chimerix (United States)), David F. Mercer(University of Nebraska at Omaha), Michael Grimley(Cincinnati Children's Hospital Medical Center)
Cited by 2
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study
|Clinical Infectious Diseases|2020|407
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369